The Priority Review

Clinical trials Brief

Biohaven registers Phase 2b/3 study of BHV-1300 in Graves' Disease

The study, led by Biohaven Therapeutics Ltd., plans to enroll an estimate of 356 participants to evaluate the safety and tolerability of BHV-1300 in adults with Graves' Disease. It plans to start in October 2026 and reach primary completion in December 2028.

Primary source

ClinicalTrials.gov registry record, October 28, 2026

An Open-Label Study to Determine if BHV-1300 is Safe in Adults With Graves' Disease

Read the source: An Open-Label Study to Determine if BHV-1300 is Safe in Adults With Graves' Disease clinicaltrials.gov

Machine-summarized from the source above; not independently reported. How we use automation